Litigation Details for Harmony Biosciences, LLC v. Lupin Limited (D. Del. 2023)

Harmony Biosciences, LLC v. Lupin Limited (D. Del. 2023)

Docket		Date Filed	2023-11-09
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	HIKMA PHARMACEUTICALS USA INC.
Patents	8,207,197; 8,354,430; 8,486,947
Attorneys	Timothy P. Heaton
Firms	Benesch, Friedlander, Coplan & Aronoff LLP
Link to Docket	External link to docket

Details for Harmony Biosciences, LLC v. Lupin Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-09				External link to document
2023-11-09	3	ANDA Form	Expiration of Patent: U.S. Patent No. 8,486,947 expires on 9/26/2029; and U.S. Patent No. 8,207,197 expires … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 9 November 2023 1:23-cv-01286 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-11-09	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,486,947 B2; 8,207,197 B2. (mkr) (Entered… 9 November 2023 1:23-cv-01286 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Harmony Biosciences, LLC v. Lupin Limited Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Harmony Biosciences, LLC and Lupin Limited concerning Harmony's narcolepsy drug, Wakix (pitolisant). The dispute centers on Lupin's proposed generic version of Wakix and the validity of Harmony's U.S. Patent No. 11,045,704. Harmony alleges infringement, while Lupin seeks to invalidate the patent.

What Are the Core Issues in the Litigation?

The central conflict revolves around patent infringement and validity. Harmony Biosciences asserts that Lupin Limited's planned generic version of Wakix infringes U.S. Patent No. 11,045,704. Lupin, in response, challenges the validity of this patent, contending it is unenforceable. This is a standard Paragraph IV certification under the Hatch-Waxman Act, where a generic manufacturer declares that a patent covering a branded drug is invalid, unenforceable, or will not be infringed by the generic product [1].

What is the Subject of the Dispute?

The subject of the dispute is Harmony Biosciences' prescription medication Wakix (pitolisant). Wakix is approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Pitolisant is a first-in-class histamine H3 receptor antagonist/inverse agonist [2, 3]. Lupin Limited seeks to market a generic version of this drug.

Which Patent is at the Heart of the Litigation?

The patent at the heart of the litigation is U.S. Patent No. 11,045,704, titled "Pitolisant salts and processes for their preparation." This patent is listed in the FDA's Orange Book for Wakix [1, 4]. The '704 patent claims specific crystalline forms of pitolisant, which are crucial for drug formulation and stability.

What Are Harmony Biosciences' Claims?

Harmony Biosciences alleges that Lupin Limited's proposed generic pitolisant product infringes claims 1-3 and 11 of U.S. Patent No. 11,045,704. Harmony asserts that Lupin's generic formulation will utilize or be equivalent to the patented crystalline forms, thereby infringing the patent rights [1].

What Are Lupin Limited's Defenses?

Lupin Limited's primary defense is that U.S. Patent No. 11,045,704 is invalid and/or unenforceable. Specific arguments from Lupin include:

• Invalidity: Lupin likely argues that the claims of the '704 patent are anticipated by prior art, obvious over prior art, or not adequately supported by the patent's specification. This often involves challenging the novelty or non-obviousness of the claimed crystalline forms of pitolisant [1].
• Non-infringement: Lupin may also argue that its proposed generic product does not practice the claims of the '704 patent, potentially by using different crystalline forms or formulations.

What is the Procedural History of the Case?

The litigation was initiated by Harmony Biosciences, indicating they believe Lupin's actions constitute direct infringement.

When Was the Lawsuit Filed?

Harmony Biosciences filed the lawsuit on September 19, 2023, in the U.S. District Court for the District of Delaware [1]. This filing followed Lupin's submission of an Abbreviated New Drug Application (ANDA) seeking approval for its generic pitolisant product.

What Type of Action is This?

This is an Abbreviated New Drug Application (ANDA) litigation filed under 35 U.S.C. § 271(e)(2)(A), commonly referred to as a Hatch-Waxman litigation. This statute allows the patent holder of a brand-name drug to sue a generic manufacturer upon receiving notice of an ANDA filing for infringement of a patent listed in the FDA's Orange Book [5].

What is the Current Status of the Case?

As of the filing date of this analysis, the case is in its early stages. Discovery is likely underway, and the court may schedule further proceedings, including claim construction (Markman hearing) and potentially summary judgment motions. The outcome will significantly impact generic competition for Wakix.

What is the Background of the Involved Parties?

Harmony Biosciences is the developer and marketer of Wakix, while Lupin Limited is a generic pharmaceutical company.

Who is Harmony Biosciences, LLC?

Harmony Biosciences, LLC is a biopharmaceutical company focused on developing and commercializing treatments for patients with rare neurological disorders, particularly sleep disorders. The company's lead product is Wakix. Harmony acquired the rights to pitolisant in the U.S. and Europe from Bioprojet [2].

Who is Lupin Limited?

Lupin Limited is a global pharmaceutical company headquartered in India. It develops, manufactures, and markets a broad range of branded and generic formulations, active pharmaceutical ingredients (APIs), and biotechnology products. Lupin is a significant player in the global generics market, including the U.S. [6].

What is the Patent Landscape for Wakix?

Harmony Biosciences holds multiple patents related to pitolisant and its uses. U.S. Patent No. 11,045,704 is a key patent in this portfolio, but others may also be relevant to the drug's commercialization and future litigation.

What Other Patents Protect Wakix?

Harmony Biosciences has a portfolio of patents covering pitolisant. While the '704 patent is central to this specific litigation, other patents may cover:

• Methods of treating narcolepsy with pitolisant.
• Specific dosage regimens.
• Manufacturing processes for pitolisant or its intermediates.
• Other crystalline forms or polymorphs of pitolisant.

The FDA's Orange Book lists patents associated with approved drugs. A review of the Orange Book for Wakix (pitolisant) would reveal the full scope of patents Harmony asserts protection for [4].

What are the Key Legal Arguments and Potential Outcomes?

The litigation hinges on the validity of the asserted patent claims and whether Lupin's generic product infringes them.

How Will Patent Validity Be Assessed?

Patent validity will be assessed based on U.S. patent law, particularly 35 U.S.C. § 101 (patentable subject matter), § 102 (novelty), § 103 (obviousness), and § 112 (written description and enablement). Lupin will likely argue that the claimed crystalline forms of pitolisant were either known or would have been obvious to a person skilled in the art at the time of filing, based on existing scientific literature or patents related to pitolisant or similar compounds [1].

What is the Standard for Infringement?

Under 35 U.S.C. § 271, infringement occurs if a party makes, uses, offers to sell, or sells a patented invention without authority. In ANDA litigation, infringement is often established by demonstrating that the generic drug, if approved, would infringe the patent claims. This involves comparing the generic product's composition and manufacturing process to the scope of the patent claims [5].

What Are the Potential Outcomes?

Several outcomes are possible in this type of litigation:

• Harmony Wins: If the court finds the '704 patent valid and infringed, Lupin's ANDA approval could be delayed, and Harmony may be granted a 30-month stay of FDA approval, or until the patent expires, whichever comes first. This would extend Harmony's market exclusivity.
• Lupin Wins: If the court finds the '704 patent invalid or not infringed, Lupin could receive FDA approval for its generic product sooner, leading to generic competition and a decrease in Wakix's market share and price.
• Settlement: The parties may reach a settlement agreement, which could involve a licensing agreement for Lupin to market a generic version of Wakix after a certain date, often with a specified royalty payment.
• Partial Victory: One party might prevail on some claims or arguments, while the other prevails on others, leading to a more complex resolution.

What is the Market Impact of This Litigation?

The outcome of this litigation will significantly influence the market for narcolepsy treatments, specifically for EDS.

How Does This Litigation Affect Generic Entry?

This litigation directly impacts the timeline for generic entry of pitolisant. A favorable outcome for Harmony Biosciences will delay or prevent Lupin's generic entry, maintaining Harmony's market exclusivity for Wakix. Conversely, a victory for Lupin would pave the way for generic competition, potentially leading to lower drug prices and increased patient access.

What is the Commercial Significance of Wakix?

Wakix represents a significant revenue stream for Harmony Biosciences. The introduction of generic competition typically leads to a substantial decline in sales for the branded drug due to price competition. Therefore, defending its patent portfolio is critical for Harmony's financial performance.

What is the Projected Market for Pitolisant Generics?

The market for EDS treatments is substantial, and generic entry often unlocks significant market growth through lower price points. The projected market size for pitolisant generics will depend on the speed and extent of generic competition following any patent challenges.

Key Takeaways

• Harmony Biosciences is suing Lupin Limited for alleged infringement of U.S. Patent No. 11,045,704, which covers crystalline forms of pitolisant, the active ingredient in Harmony's narcolepsy drug Wakix.
• Lupin Limited denies infringement and challenges the validity of the '704 patent, a common defense in Paragraph IV Hatch-Waxman litigation.
• The litigation will determine the timeline for generic entry of pitolisant, directly impacting Harmony's market exclusivity and pricing for Wakix.
• The U.S. District Court for the District of Delaware is presiding over the case, which is currently in its early stages.

Frequently Asked Questions

1. What is a Paragraph IV certification? A Paragraph IV certification is filed by a generic drug manufacturer with the FDA, asserting that the patent(s) covering the brand-name drug are invalid, unenforceable, or will not be infringed by the generic product. This action typically triggers patent litigation.

2. What is the significance of U.S. Patent No. 11,045,704? This patent claims specific crystalline forms of pitolisant, which are crucial for the stability, manufacturability, and efficacy of the drug product. Its validity and enforceability are central to Harmony's ability to maintain market exclusivity for Wakix.

3. What is the role of the FDA in this litigation? The FDA is responsible for approving drug applications. In the context of ANDA litigation, the FDA will typically hold approval of Lupin's generic application for 30 months from the date it receives notice of the patent infringement lawsuit, unless the litigation is resolved sooner, the patent expires, or the court rules in favor of the generic manufacturer.

4. What are the potential consequences if Harmony Biosciences loses this case? If Harmony loses, Lupin Limited could receive approval to market its generic pitolisant product sooner, leading to immediate price competition and a significant reduction in Wakix's market share and revenue.

5. Can other generic companies also challenge Harmony's patents? Yes, other generic pharmaceutical companies seeking to market a generic version of Wakix would likely also file Paragraph IV certifications and potentially face similar patent litigation if they target patents listed in the Orange Book.

---

[1] Harmony Biosciences, LLC v. Lupin Limited, No. 1:23-cv-01286 (D. Del. Sept. 19, 2023). [2] Harmony Biosciences. (n.d.). Wakix® (pitolisant). Retrieved from https://www.harmonybiosciences.com/wakix/ [3] U.S. Food & Drug Administration. (2023, November 21). Drug Approval Packages: Wakix. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021301Orig1s000,021301s001,021301s002,021301s003,021301s004,021301s005,021301s006.cfm [4] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [5] Hatch-Waxman Act Amendments of 1984, Pub. L. No. 98-417, 98 Stat. 1585. [6] Lupin Limited. (n.d.). About Us. Retrieved from https://www.lupin.com/in/about-us/